Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer

References

• Rahib L, Smith BD, Aizenberg R, et al. (2014). Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913–21.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. (2016). Cancer facts and figures 2016. Atlanta, GA: American Cancer Society.
   Google Scholar
• Malik NK, May KS, Chandrasekhar R, et al. (2012). Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. J Gastrointest Oncol 3:326–34.
   PubMedGoogle Scholar
• Geer RJ, Brennan MF. (1993). Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165:68–72.
   PubMed Web of Science ®Google Scholar
• Lim JE, Chien MW, Earle CC. (2003). Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 237:74–85.
   PubMed Web of Science ®Google Scholar
• Ueda M, Endo I, Nakashima M, et al. (2009). Prognostic factors after resection of pancreatic cancer. World J Surg 33:104–10.
   PubMed Web of Science ®Google Scholar
• Yu M, Tannock IF. (2012). Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell 21:327–9.
   PubMed Web of Science ®Google Scholar
• Yu X, Zhang Y, Chen C, et al. (2010). Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta 1805:97–104.
   PubMed Web of Science ®Google Scholar
• Burris HA, Moore MJ, Andersen J, et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–13.
   PubMed Web of Science ®Google Scholar
• Izeradjene K, Hingorani SR. (2007). Targets, trials, and travails in pancreas cancer. J Natl Compr Cancer Netw 5:1042–53.
   PubMedGoogle Scholar
• Erkan M, Hausmann S, Michalski CW, et al. (2012). The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 9:454–67.
   PubMed Web of Science ®Google Scholar
• DuFort CC, DelGiorno KE, Carlson MA, et al. (2016). Interstitial pressure in pancreatic ductal adenocarcinoma is dominated by a gel-fluid phase. Biophys J 110:2106–19.
   PubMed Web of Science ®Google Scholar
• Provenzano PP, Cuevas C, Chang AE, et al. (2012). Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21:418–29.
   PubMed Web of Science ®Google Scholar
• Jacobetz MA, Chan DS, Neesse A, et al. (2013). Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62:112–20.
   PubMed Web of Science ®Google Scholar
• Provenzano PP, Hingorani SR. (2013). Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer 108:1–8.
   PubMed Web of Science ®Google Scholar
• DuFort CC, DelGiorno KE, Hingorani SR. (2016). Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma. Gastroenterology 150:1545–57.e2.
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Wang L, Multani AS, et al. (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469–83.
   PubMed Web of Science ®Google Scholar
• Olive KP, Tuveson DA. (2006). The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 12:5277–87.
   PubMed Web of Science ®Google Scholar
• Dromi S, Frenkel V, Luk A, et al. (2007). Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 13:2722–7.
   PubMed Web of Science ®Google Scholar
• Issels RD, Lindner LH, Verweij J, et al. (2010). Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 11:561–70.
   PubMed Web of Science ®Google Scholar
• Park K. (2013). Improved tumor targeting by mild hyperthermia. J Control Release 167:220.
   PubMed Web of Science ®Google Scholar
• Kong G, Anyarambhatla G, Petros WP, et al. (2000). Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 60:6950–7.
   PubMed Web of Science ®Google Scholar
• Kong G, Dewhirst MW. (1999). Hyperthermia and liposomes. Int J Hyperthermia 15:345–70.
   PubMed Web of Science ®Google Scholar
• Needham D, Anyarambhatla G, Kong G, Dewhirst MW. (2000). A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 60:1197–201.
   PubMed Web of Science ®Google Scholar
• Landon CD, Park JY, Needham D, Dewhirst MW. (2011). Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. Open Nanomed J 3:38–64.
   PubMedGoogle Scholar
• Ta T, Porter TM. (2013). Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. J Control Release 169:112–25.
   PubMed Web of Science ®Google Scholar
• Maloney E, Hwang JH. (2015). Emerging HIFU applications in cancer therapy. Int J Hyperthermia 31:302–9.
   PubMed Web of Science ®Google Scholar
• Haar GT, Coussios C. (2007). High intensity focused ultrasound: physical principles and devices. Int J Hyperthermia 23:89–104.
   PubMed Web of Science ®Google Scholar
• Negussie AH, Yarmolenko PS, Partanen A, et al. (2011). Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound. Int J Hyperthermia 27:140–55.
   PubMed Web of Science ®Google Scholar
• de Smet M, Heijman E, Langereis S, et al. (2011). Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof-of-concept study. J Control Release 150:102–10.
   PubMed Web of Science ®Google Scholar
• Salomir R, Vimeux FC, de Zwart JA, et al. (2000). Hyperthermia by MR-guided focused ultrasound: accurate temperature control based on fast MRI and a physical model of local energy deposition and heat conduction. Magn Reson Med 43:342–7.
   PubMed Web of Science ®Google Scholar
• Staruch RM, Hynynen K, Chopra R. (2015). Hyperthermia-mediated doxorubicin release from thermosensitive liposomes using MR-HIFU: therapeutic effect in rabbit Vx2 tumours. Int J Hyperthermia 31:118–33.
   PubMed Web of Science ®Google Scholar
• Treat LH, McDannold N, Vykhodtseva N, et al. (2007). Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 121:901–7.
   PubMed Web of Science ®Google Scholar
• Hijnen N, Langereis S, Grull H. (2014). Magnetic resonance guided high-intensity focused ultrasound for image-guided temperature-induced drug delivery. Adv Drug Deliv Rev 72:65–81.
   PubMed Web of Science ®Google Scholar
• Ishihara Y, Calderon A, Watanabe H, et al. (1995). A precise and fast temperature mapping using water proton chemical shift. Magn Reson Med 34:814–23.
   PubMed Web of Science ®Google Scholar
• Enholm JK, Kohler MO, Quesson B, et al. (2010). Improved volumetric MR-HIFU ablation by robust binary feedback control. IEEE Trans Bio-Med Eng 57:103–13.
   PubMed Web of Science ®Google Scholar
• Partanen A, Yarmolenko PS, Viitala A, et al. (2012). Mild hyperthermia with magnetic resonance-guided high-intensity focused ultrasound for applications in drug delivery. Int J Hyperthermia 28:320–36.
   PubMed Web of Science ®Google Scholar
• Olsen DR, Singstad TE, Rofstad EK. (1999). Effects of hyperthermia on bioenergetic status and phosphorus T1S in human melanoma xenografts monitored by 31P-MRS. Magn Reson Imaging 17:1049–56.
   PubMed Web of Science ®Google Scholar
• Al-Abd AM, Kim NH, Song SC, et al. (2009). A simple HPLC method for doxorubicin in plasma and tissues of nude mice. Arch Pharm Res 32:605–11.
   PubMed Web of Science ®Google Scholar
• Li T, Wang YN, Khokhlova TD, et al. (2015). Pulsed high-intensity focused ultrasound enhances delivery of doxorubicin in a preclinical model of pancreatic cancer. Cancer Res 75:3738–46.
   PubMed Web of Science ®Google Scholar
• Hildebrandt B, Wust P, Ahlers O, et al. (2002). The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 43:33–56.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Overgaard J. (1997). Can mild hyperthermia improve tumour oxygenation? Int J Hyperthermia 13:1417.
   Web of Science ®Google Scholar
• Song CW, Park H, Griffin RJ. (2001). Improvement of tumor oxygenation by mild hyperthermia. Radiat Res 155:515–28.
   PubMed Web of Science ®Google Scholar
• Song CW, Park HJ, Lee CK, Griffin R. (2005). Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 21:761–7.
   PubMed Web of Science ®Google Scholar
• Kirui DK, Mai J, Palange AL, et al. (2014). Transient mild hyperthermia induces E-selectin mediated localization of mesoporous silicon vectors in solid tumors. PLoS One 9:e86489.
   PubMed Web of Science ®Google Scholar
• Grull H, Langereis S. (2012). Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound. J Control Release 161:317–27.
   PubMed Web of Science ®Google Scholar
• de Smet M, Hijnen NM, Langereis S, et al. (2013). Magnetic resonance guided high-intensity focused ultrasound mediated hyperthermia improves the intratumoral distribution of temperature-sensitive liposomal doxorubicin. Invest Radiol 48:395–405.
   PubMed Web of Science ®Google Scholar
• Mills JK, Needham D. (2005). Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochim Biophys Acta 1716:77–96.
   PubMed Web of Science ®Google Scholar
• Debbage PL, Griebel J, Ried M, et al. (1998). Lectin intravital perfusion studies in tumor-bearing mice: micrometer-resolution, wide-area mapping of microvascular labeling, distinguishing efficiently and inefficiently perfused microregions in the tumor. J Histochem Cytochem 46:627–39.
   PubMed Web of Science ®Google Scholar
• Minchinton AI, Tannock IF. (2006). Drug penetration in solid tumours. Nat Rev Cancer 6:583–92.
   PubMed Web of Science ®Google Scholar
• Yagublu V, Caliskan N, Lewis AL, et al. (2013). Treatment of experimental pancreatic cancer by doxorubicin-, mitoxantrone-, and irinotecan-drug eluting beads. Pancreatology 13:79–87.
   PubMed Web of Science ®Google Scholar
• Mita MM, Natale RB, Wolin EM, et al. (2015). Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Invest New drugs 33:341–8.
   PubMed Web of Science ®Google Scholar
• Manzoor AA, Lindner LH, Landon CD, et al. (2012). Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res 72:5566–75.
   PubMed Web of Science ®Google Scholar